Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

[Preprint]. 2020 Jun 30:rs.3.rs-39128. [Version 1] doi: 10.21203/rs.3.rs-39128/v1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This work is licensed under a Creative Commons Attribution 4.0 International License, which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use.

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

PMC Copyright notice

(a) The network of drugs targeting the host (human) proteins interacting with SARS-Cov-1 and SARS-Cov-2. The light green nodes are the drugs that downregulate the expression of the host genes that interact with SARS-Cov-1 or SARS-Cov-2. The interactions of SARS-Cov-2 with host proteins are collected from Gordon et al.9; the drugs targeting the host proteins are collected from DrugBank and DGIdb10,11; and the drug-induced changes in gene expression (time- and dose-dependent) in cell lines are collected from CMAP14. The dark green nodes are currently in clinical trials for COVID-19 (collected from literature). (b) The map shows the drugs from Figure 3a that significantly affect the pathways upregulated (cyan column-side colors) or downregulated (purple column-side colors) in SARS and COVID-19 infection. Blue cells indicate the pathway gets significantly downregulated by the drug (p < 0.05), while red indicates the pathway gets significantly upregulated by the drug in a time-dependent manner (measured by differences in pathway ssGSEA scores at 24 hours vs. 6 hours of drug treatment from CMAP). (c-d) The boxplots show the differences in ssGSEA scores for the pathways KEGG_Proteasomes (high in SARS and COVID-19 infection) and BIOCARTA_CTL_pathway (low in SARS and COVID-19 infection) at 6 hours vs. 24 hours of treatment with the drug cytarabine. Significant downregulation of KEGG_Proteasomes and significant upregulation of BIOCARTA_CTL_pathway are seen as an effect of cytarabine at 24 hours compared to 6 hours (cell line drug treatment data from CMAP).